Stimufend

Fresenius Kabi introduces pegfilgrastim biosimilar for cancer patients in US
Pharmaceutical Business Review
Fri, 02/17/23 - 09:44 am
Fresenius Kabi
Stimufend
pegfilgrastim
biosimilars
Neulasta
Amgen
cancer
Amgen's Neulasta gains another biosimilar competitor as sales slip
Endpoints
Thu, 09/8/22 - 04:35 pm
Amgen
Neulasta
Fresenius Kabi
biosimilars
FDA
Stimufend